Curated News
By: NewsRamp Editorial Staff
August 13, 2026
NeuroOne Reports Q3 Revenue Growth, Backlog Up, StereoCED Launch Ahead
TLDR
- NeuroOne's product orders surged 43% to $2.7M, outpacing shipments; backlog $1.7M signals strong demand and growth potential.
- NeuroOne received ISO 13485 certification, boosting international commercialization; expects StereoCED availability for studies by year-end.
- NeuroOne's StereoCED platform aims to treat childhood brain cancer and epilepsy, potentially improving outcomes for patients with neurological disorders.
- NeuroOne's StereoCED platform could enable brain drug delivery, potentially transforming treatment for conditions like pediatric DMG.
Impact - Why it Matters
This news matters because NeuroOne's advancements in drug delivery and ablation technologies could transform treatments for neurological disorders like epilepsy and brain cancer, potentially improving patient outcomes and expanding market opportunities. The company's revenue growth and expanding margins signal financial health, while its strategic collaborations and international certification position it for broader commercial success, making it a key player to watch in the medtech space.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on neurological disorders, reported its fiscal Q3 2026 financial results, showing a 16% increase in product revenue to $2.0 million compared to the same period last year. The company received $2.7 million in new product orders during the quarter, a 43% year-over-year growth, which outpaced shipments and resulted in a backlog of $1.7 million. Product gross margins expanded to a record 59.9%, up from 53.9% in the prior year, driven by a favorable sales mix. CEO Dave Rosa highlighted the company's progress, including the upcoming launch of its StereoCED™ drug delivery platform for research and investigational studies, continued growth of the OneRF® Brain Ablation System, and international expansion plans after receiving ISO 13485 certification.
NeuroOne's StereoCED™ platform, designed for CNS drug delivery, has gained traction through collaborations with the Mayo Clinic and the University of Minnesota, focusing on pediatric brain cancer and epilepsy treatments. The company also released a white paper on the platform's potential to reduce procedure time and address barriers to scalable brain therapeutics. Additionally, a study published in the Journal of Neurosurgery validated the use of NeuroOne's OneRF® system in patients with implanted neuromodulation devices, expanding the treatable patient pool. The company is also advancing its basivertebral nerve ablation system for lower back pain, with discussions underway with a tier-one partner.
Financially, NeuroOne raised $1.4 million through its ATM program post-quarter-end, and its lead investor increased ownership to 12.5%. The company has no debt and working capital of $3.7 million as of June 30, 2026. Management will host a conference call today at 8:30 a.m. Eastern time to discuss these results and provide an update. The company's inclusion in the Russell Microcap Index underscores its growth trajectory.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, NeuroOne Reports Q3 Revenue Growth, Backlog Up, StereoCED Launch Ahead
